Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
zelicapavir · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| zelicapavir | EXPERIMENTAL | zelicapavir, oral suspension, once daily for 7 days |
| Placebo | PLACEBO_COMPARATOR | Matching placebo, orally, once daily for 7 days |
| zelicapavir Dose 1 (therapeutic dose) | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| zelicapavir Dose 2 (supratherapeutic dose) | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| moxifloxacin | EXPERIMENTAL | All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25. |
| Name | Type | Description |
|---|---|---|
| zelicapavir | DRUG | Oral suspension |
| Placebo | DRUG | Placebo oral suspension to match zelicapavir |
| zelicapavir (therapeutic dose) | DRUG | Subjects will receive zelicapavir (TD) once per treatment period. |
| zelicapavir (supratherapeutic dose) | DRUG | Subjects will receive zelicapavir (SD) once per treatment period. |
| moxifloxacin | DRUG | Subjects will receive moxifloxin once per treatment period. |
Inclusion Criteria: * Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza * Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization * In the Investigator's op...
Top 20 of 28 competitors
Zelicapavir is an investigational small molecule being developed for the treatment of respiratory syncytial virus (RSV) infection. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Zelicapavir is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ENTA.
Zelicapavir is in Phase 2 clinical development for RSV infection. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
Zelicapavir has two clinical trials. A completed Phase 1 study (NCT06601192) evaluated its effects on QTc interval in healthy adults. An ongoing Phase 2 study (NCT07482657) is recruiting participants aged 28 days to 36 months with RSV infection in Thailand.
Zelicapavir is a small molecule antiviral. Its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.
Yes, zelicapavir is also known as EDP-938. The Phase 1 trial title refers to zelicapavir (EDP-938), confirming that both names refer to the same investigational drug.